BioMarin Pharmaceutical (NASDAQ:BMRN) Announces FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.800-3.100 for the period, compared to the consensus EPS estimate of 3.320. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Barclays upped their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Oppenheimer cut their price target on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating on the stock in a report on Tuesday. HC Wainwright reissued a “neutral” rating and issued a $60.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday. Finally, Jefferies Financial Group raised their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $87.91.

BioMarin Pharmaceutical Trading Up 2.6%

NASDAQ BMRN opened at $57.13 on Thursday. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56. The firm has a market cap of $11.06 billion, a PE ratio of 31.27, a price-to-earnings-growth ratio of 0.61 and a beta of 0.21. The company has a 50 day moving average price of $60.06 and a 200 day moving average price of $58.46. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.28. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. During the same period last year, the firm earned $0.12 earnings per share. BioMarin Pharmaceutical’s revenue was up 32.0% compared to the same quarter last year. As a group, sell-side analysts forecast that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.